Romanian Society of Pharmaceutical Sciences

« Back to Farmacia Journal 3/2023

EFFICACY AND SAFETY OF INTRAPERITONEAL INFUSION OF RALTITREXED IN LAPAROSCOPIC RADICAL RESECTION OF RECTAL CANCER

CHENGJIANG XIANG *, JINHAO LIANG

Department of Anorectal Surgery, Shengzhou People’s Hospital (The First Affiliated Hospital of Zhejiang University Shengzhou Branch), Shengzhou, 312400, Zhejiang, China

Download Full Article PDF

The aim of this study was to investigate the efficacy and safety of intraperitoneal infusion chemotherapy with raltitrexed during laparoscopic radical resection (LSRR) of rectal cancer (RC). Clinical data from 90 patients with rectal cancer who received chemotherapy in the hospital were retrospectively collected. According to the treatment methods, they were divided into two groups: laparoscopic rectal cancer radical resection combined with raltitrexed intraperitoneal chemotherapy (the observation group) and simple laparoscopic rectal cancer radical resection (the control group). Postoperative recovery, the incidence of postoperative complications, and changes in tumour markers were observed. The results suggested no substantial difference in postoperative recovery, complication rate, or toxic side effects between groups (p > 0.05). Carcinoembryonic antigen was 13.57 ± 11.17 in the observation group and 16.34 ± 13.73 in the control group at 3 months postoperatively. The observation group had markedly inferior carcinoembryonic antigen compared with the control group at 3 months postoperatively (p < 0.05). In the observation group, the 3-year local recurrence rate (RR) was 5 cases (11.1%), and the distant metastasis rate (MR) was 8 cases (17.8%). In the control group, the 3-year local RR was 13 cases (28.9%), and the distant MR was 17 cases (37.8%). The observation group had a greatly inferior 3-year local RR and distal MR compared to the control group (p < 0.05). Furthermore, the 3-year survival rate (SR) was 32 cases (71.1%) in the observation group and 23 cases (51.1%) in the control group. The 3-year SR of the observation group was dramatically superior to that of the control group (p < 0.05). In short, intraperitoneal raltitrexed infusion has good safety, can improve the long-term SR of patients, and can reduce the risk of recurrence and metastasis.